The earn-out used to be the clause everyone hoped to delete before signing. In European HealthTech, MedTech and Health AI it has quietly become the deal itself. A founder selling a Series B diagnostics company in Munich, a PE-backed buyer consolidating radiology AI across the Nordics, a US strategic picking up a UK remote-monitoring business: in each case, a meaningful slice of the price, often 20 to 50 per cent, now sits behind a set of post-completion conditions.